ClinicalTrials.gg
RecruitingNCT06314503CORDIALUpdated Jul 18, 2025

First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients

An interventional study of WEAKID in Renal Insufficiency, Chronic, Kidney Failure, Chronic and Chronic Kidney Diseases, sponsored by UMC Utrecht. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-18.

Primary conditionKidney Failure, ChronicRegistry: Renal Insufficiency, ChronicReclassifiedWhy we changed it
Registry
Renal Insufficiency, Chronic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's listed conditions name Kidney Failure, Chronic, a narrower term within Renal Insufficiency, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by UMC Utrecht · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Kidney Failure, Chronic with a site in Italy — 14 open to participants now, 19 under way, 4 of them phase 3. Kidney Failure, Chronic · Italy.

Planned enrollment
52nd of 59
12 · median 80
Started
2024
with 5 others
No phase
17 of 75
5 open now
Primary completion
2025-12
later than 2 of 18 live
Registered
69th of 75
by date

Among the 75 studies in Kidney Failure, Chronic with a site in Italy, this one is the 52nd largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2024, is one of 17 with no phase, reaches primary completion later than 2 of the 18 other live ones, and was the 69th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

14 of the 75 studies in Kidney Failure, Chronic with a site in Italy are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Kidney Failure, Chronic with a site in Italy, or all of them as a file.
02

Study summary

The goal of this first-in-human clinical trial is to examine the safety and efficacy of treatment with a new peritoneal dialysis (PD) device called WEAKID (WEarable Artificial KIDney for peritoneal dialysis). This device, unlike conventional PD, allows for continuous flow of dialysate inside the abdominal cavity combined with continuous regeneration of spent dialysate thanks to sorbents that remove toxins from the fluid.

The study will include PD patients of 18 years or older with a well-functioning peritoneal catheter and no history of a PD-related infection for at least eight weeks prior to enrolment.

The main purpose of this study is to assess the (short-term) safety of the WEAKID system in a limited number (n=12) of patients and sessions.

Participants will undergo six treatment sessions (of four or eight hours) in total over a period of two weeks, either with or without a sorbent chamber.

Participants will be asked to collect urine and dialysate the week before the first treatment and during the treatment days. In addition, blood samples will be collected before and during the treatment weeks in order to compare the effects of conventional PD with that of WEAKID treatment. A peritoneal equilibrium test will also be done before and after the treatment weeks to test the function of the lining of the abdomen (the peritoneal membrane).

Read the detailed description

Peritoneal dialysis (PD) is a life-sustaining renal replacement therapy for patients with end-stage kidney disease (ESKD). With PD, waste solutes and excess water are drawn from the blood across the peritoneal membrane lining the abdominal cavity via diffusion and osmosis, respectively, into dialysis fluid (peritoneal dialysate) that is introduced into the abdominal cavity through a permanent tube (peritoneal catheter). The peritoneal dialysate is replaced 4-6 times/day either manually by the patient or automatically by a machine at night while the patient is asleep. PD is a gentle dialysis technique that provides continuous gradual dialysis while the patient is free to move during the day. However, PD has several disadvantages. Removal of waste solutes is inadequate and technique failure rate is high, contributing to poor quality of life and high (co)morbidity and mortality (10-15% per year). The low solute clearance (\~1-7% of that of healthy kidneys (depending on the solute) and lower than that with haemodialysis (HD)) is due to rapid decrease of diffusive transport of solutes during a dwell due to the disappearance of the plasma-to-dialysate concentration gradient across the peritoneal membrane. The limited technique survival (median 3.7 years) is primarily due to the high incidence of recurrent infection of the peritoneal membrane (peritonitis) and exposure of the peritoneal membrane to very high, harmful glucose concentrations needed for osmotic fluid removal.

Both peritonitis and high glucose concentrations cause pathological changes of the peritoneal membrane and eventually ultrafiltration failure necessitating a switch to the more invasive and expensive HD treatment. To reduce the existing shortcomings of conventional PD, a novel continuous flow peritoneal dialysis system with dialysate regeneration (WEAKID) for PD was developed. WEAKID treatment is based on continuous recirculation of peritoneal dialysate via the single lumen peritoneal catheter with regeneration of spent dialysate by means of sorbent technology. The WEAKID nighttime system (weight: \~12 kg) is intended to be used for 8h per day (during the night) on a daily basis. Instead of performing 4-6 exchanges with fresh peritoneal dialysate per day, WEAKID uses one peritoneal dialysate filling which is continuously recirculated and regenerated. The continuous regeneration prevents saturation of the dialysate with toxins and thereby maintains a high plasma to dialysate concentration gradient which enhances diffusive transport of uremic toxins. In addition, the continuous recirculating flow of fluid along the peritoneal membrane is expected to increase the mass transfer area coefficient as observed in previous studies with continuous flow peritoneal dialysis, probably due to reduction of diffusion resistance, renewal of stagnant fluid layers at the tissue surface and an increase of the effective membrane area. Both the high plasma to dialysate concentration gradient and the increase in mass transfer contribute to an enhancement of the clearance. Another advantage of the WEAKID system is that the glucose peak load to peritoneum is lower than with traditional automated peritoneal dialysis (APD) and continuous ambulatory peritoneal dialysis (CAPD) thanks to the buffering of the sorbents (sorbents adsorb glucose at the start, lowering the initial glucose peak, and release the glucose again at later stage) and the continuous recirculation.

The primary objective of this study is to assess the (short-term) safety of the WEAKID nighttime system in a limited number (n=12) of patients and sessions (6 sessions per patient).

Secondary objectives of this study are:

  1. To evaluate the incidence of adverse events (AEs) and device deficiencies (DDs) other than serious adverse device effects (SADEs) and DDs that could have led to a serious adverse event (SAE)
  2. To describe the characteristics of WEAKID treatment (i.e. number and duration of sessions, dialysate flow rates)
  3. To evaluate the clinical condition and vital signs of the participants during WEAKID treatment
  4. To evaluate the effectiveness of ultrafiltration (UF) in relation to glucose concentration during WEAKID treatment
  5. To evaluate the efficacy of solute removal and base release of WEAKID treatment
  6. To evaluate the evolution of plasma analytes during WEAKID treatment
  7. To evaluate the evolution of dialysate effluent analytes of the WEAKID system
  8. To evaluate the (technical) device performance of the WEAKID system by the number of device deficiencies, adverse device effects and changes in intraperitoneal pressure
  9. To evaluate patient tolerance during WEAKID treatment
  10. To evaluate the evolution of uremic symptoms during WEAKID treatment
  11. To evaluate the effectiveness of using sorbents for dialysate regeneration and the effectiveness of continuous recirculating flow in relation to the efficacy of solute removal.

The WEAKID system will be tested in a clinical setting on 6 days over a period of 2 weeks. During the first week, the subjects will be treated with the nighttime system without sorbents for 4h (first day) or 8h (second and third day) during daytime. The second week, treatment will consist of the nighttime system with sorbents (also 4h (first day) or 8h (second and third day) during daytime).

This way, exposure to new components of the system is incremental and the effectiveness of the sorbents can be analyzed separately from the effect of continuous recirculating flow dialysis. A peritoneal equilibration test (PET) will be performed at baseline and follow-up. In addition, patients will collect 24h spent peritoneal dialysate and 24h urine followed by venous puncture for blood sampling 3 times prior to WEAKID treatment during standard PD.

03

Conditions studied

  • Renal Insufficiency, Chronic
  • Kidney Failure, Chronic
  • Chronic Kidney Diseases

Browse trials for

Keywords

  • Peritoneal Dialysis
  • First-in-human
  • Medical device
04

In context

Kidney Failure, Chronic Reclassified

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

This study's planned enrollment of 12 is below the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

UMC Utrecht is the lead sponsor of 364 studies on the registry; 81 are open to participants now.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • Treated with PD for at least 3 months prior to enrolment
  • Well-functioning peritoneal catheter and no peritoneal catheter replacement for at least a month prior to enrolment
  • No PD-related infection (exit-site infection, tunnel infection or peritonitis) less than 8 weeks prior to enrolment (counting from the day that the treatment has been finished).
  • Previous or current use of Extraneal® with no
  • Capable of understanding the patient information sheet and form (ICF) and give informed consent
  • Willing and able to comply with all study procedures and attend all study visits

Exclusion criteria

Exclusion Criteria:

  • Patients who are unable to provide
  • Patients who are unable to comply with study procedures
  • Patients who received renal replacement therapy other than conventional PD less than 8 weeks prior to enrolment
  • Patients who participated in an intervention trial less than 8 weeks prior to enrolment or are currently participating in an intervention trial. Patients in an observational study without any interventions or in post-market surveillance do not need to be excluded.
  • Patients with a PD-related infection (exit-site infection, tunnel infection or peritonitis) less than 8 weeks prior to enrolment (counting from the day that the treatment has been finished)
  • Patients with peritoneal catheter dysfunction or mechanical issues less than one month prior to enrolment
  • Patients who have never used Extraneal® dialysis fluid or have a for Extraneal®: a known allergy to cornstarch or icodextrin; maltose or isomaltose intolerance; glycogen storage disease
  • Patients with an incompatible PD connection to the device (e.g. Fresenius PD system)
  • Patients with concentrations \< 6.2 mmol/L (\< 10 g/dL) less than 8 weeks prior to enrolment
  • Patients with hyperkalemia (> 6.0 mmol/L) or hyponatremia (\< 130 mmol/L) in the 8 weeks prior to enrolment
  • Patients with hypocalcemia (plasma total calcium concentration corrected for albumin \<2.20 mmol/L or ionized calcium \<1.15 mmol/L) or hypomagnesemia (plasma magnesium concentration \<0.70 mmol/L) in the 8 weeks prior to enrolment
  • Patients with any serious medical condition which in the opinion of the investigator, may adversely affect the safety of the participant and/or effectiveness of the study
  • Female patients who are either (planning to become) pregnant within the study period or breast feeding
  • Patients with a \<3 months
  • Anticipated living donor kidney transplantation \<3 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    WEAKID

    Six treatments over the course of two weeks with the WEAKID system

    Device: WEAKID

Interventions

  • DeviceWEAKID

    Six treatments over the course of two weeks with the WEAKID system: * Week 1 (without the sorbents) * Day 1: four-hour treatment * Day 2: eight-hour treatment * Day 3: eight-hour treatment * Week 2 (with the sorbents) * Day 1: four-hour treatment * Day 2: eight-hour treatment * Day 3: eight-hour treatment

    Also known as: CORDIAL

07

What researchers measure

Primary outcomes

  1. Serious adverse device effects (SADEs) and device deficiencies (DDs)

    Serious adverse device effects (SADEs) and device deficiencies (DDs) that could have led to a serious adverse event

    Time frame: This will be assessed through study completion (four weeks in total per participant)

  2. Critical changes in blood pressure

    Critical changes requiring intervention in blood pressure (measured in mmHg; both systolic and diastolic pressures will be assessed).

    Time frame: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  3. Critical changes in heart rate

    Critical changes requiring intervention in heart rate (measured in beats per minute).

    Time frame: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  4. Critical changes in body temperature

    Critical changes requiring intervention in body temperature (measured in °C).

    Time frame: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  5. Critical changes in oxygen saturation

    Critical changes requiring intervention in oxygen saturation (measured in %).

    Time frame: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  6. Critical changes in plasma potassium

    Critical changes requiring intervention in plasma potassium (before and after WEAKID treatment in mmol/L).

    Time frame: This will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  7. Critical changes in plasma calcium

    Critical changes requiring intervention in plasma calcium (before and after WEAKID treatment in mmol/L).

    Time frame: This will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  8. Critical changes in plasma bicarbonate

    Critical changes requiring intervention in plasma bicarbonate (before and after WEAKID treatment in mmol/L).

    Time frame: This will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  9. Critical changes in intra-abdominal dialysate volume

    Critical changes requiring intervention in intra-abdominal dialysate volume.

    Time frame: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  10. Critical changes in intra-abdominal pressure

    Critical changes requiring intervention in intra-abdominal dialysate pressure (in mbar).

    Time frame: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

Secondary outcomes

  1. Adverse events (AEs) and device deficiencies (DDs)

    Assessing incidence of adverse events (AEs) and device deficiencies (DDs) other than SADEs and DDs that could have led to an serious adverse event (SAE).

    Time frame: This will be assessed through study completion (four weeks in total per participant)

  2. Number of WEAKID treatments

    The number of WEAKID treatments per patient will be determined

    Time frame: The number of WEAKID treatments will be assessed for the study treatment period (2 weeks in total per participant)

  3. Duration of WEAKID treatments

    Duration of each WEAKID treatment will be assessed (in minutes).

    Time frame: This will be assessed for each WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  4. Dialysate flow rates during WEAKID treatment

    Dialysate flow rates will be determined during each WEAKID treatment (in mL/min).

    Time frame: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  5. Evolution of blood pressure

    Blood pressure will be measured multiple times during a WEAKID treatment to examine its evolution during treatment (in mmHg).

    Time frame: This will be assessed during WEAKID treatment at t=0 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  6. Evolution of heart rate

    Heart rate will be measured multiple times during a WEAKID treatment to examine its evolution during treatment (in beats per minute).

    Time frame: This will be assessed during WEAKID treatment at t=0 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  7. Evolution of body temperature

    Body temperature will be measured multiple times during a WEAKID treatment to examine its evolution during treatment (in °C).

    Time frame: This will be assessed during WEAKID treatment at t=0 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  8. Evolution of oxygen saturation

    Oxygen saturation will be measured multiple times during a WEAKID treatment to examine its evolution during treatment (in %).

    Time frame: This will be assessed during WEAKID treatment at t=0 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  9. Ultrafiltration volume

    For each WEAKID session, ultrafiltration volume will be determined (in mL).

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  10. Peak glucose concentration in the device effluent

    For each WEAKID session, peak glucose concentration in the effluent of the device will be determined (in mmol/L).

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  11. Ultrafiltration efficiency

    For each session, ultrafiltration efficiency (volume of osmotic water removal per gram absorbed glucose) will be determined (in mL/gram absorbed glucose).

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  12. Removal of urea by the WEAKID system

    The removal of urea (in mmol) by the WEAKID system will be determined for each WEAKID treatment

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  13. Removal of creatinine by the WEAKID system

    The removal of creatinine (in mmol) by the WEAKID system will be determined for each WEAKID treatment

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  14. Removal of phosphate by the WEAKID system

    The removal of phosphate (in mmol) by the WEAKID system will be determined for each WEAKID treatment

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  15. Removal of potassium by the WEAKID system

    The removal of potassium (in mmol) by the WEAKID system will be determined for each WEAKID treatment

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  16. Removal of beta-2 microglobulin by the WEAKID system

    The removal of beta-2 microglobulin (in mmol) by the WEAKID system will be determined for each WEAKID treatment

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  17. Mass transfer area coefficient of urea

    The mass transfer area coefficient (MTAC) for urea will be determined for each WEAKID treatment (in mL/min)

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  18. Mass transfer area coefficient of creatinine

    The mass transfer area coefficient (MTAC) for creatinine will be determined for each WEAKID treatment (in mL/min)

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  19. Mass transfer area coefficient of phosphate

    The mass transfer area coefficient (MTAC) for phosphate will be determined for each WEAKID treatment (in mL/min)

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  20. Mass transfer area coefficient of potassium

    The mass transfer area coefficient (MTAC) for potassium will be determined for each WEAKID treatment (in mL/min)

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  21. Mass transfer area coefficient of beta-2 microglobulin

    The mass transfer area coefficient (MTAC) for beta-2 microglobulin will be determined for each WEAKID treatment (in mL/min)

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  22. Plasma clearance of urea

    The plasma clearance of urea will be determined for each WEAKID treatment (in mL/min)

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  23. Plasma clearance of creatinine

    The plasma clearance of creatinine will be determined for each WEAKID treatment (in mL/min)

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  24. Plasma clearance of phosphate

    The plasma clearance of phosphate will be determined for each WEAKID treatment (in mL/min)

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  25. Plasma clearance of potassium

    The plasma clearance of potassium will be determined for each WEAKID treatment (in mL/min)

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  26. Plasma clearance of beta-2 microglobulin

    The plasma clearance of beta-2 microglobulin will be determined for each WEAKID treatment (in mL/min)

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  27. The plasma reduction ratio of the protein-bound uremic toxin p-cresyl sulfate

    The plasma reduction ratio of p-cresyl sulfate will be calculated using the plasma concentrations before and after each WEAKID treatment.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  28. The plasma reduction ratio of the protein-bound uremic toxin p-cresyl glucuronide

    The plasma reduction ratio of p-cresyl glucuronide will be calculated using the plasma concentrations before and after WEAKID treatment.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  29. The plasma reduction ratio of the protein-bound uremic toxin indole acetic acid

    The plasma reduction ratio of indole acetic acid will be calculated using the plasma concentrations before and after WEAKID treatment.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  30. The plasma reduction ratio of the protein-bound uremic toxin kynurenine

    The plasma reduction ratio of kynurenine will be calculated using the plasma concentrations before and after WEAKID treatment.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  31. The plasma reduction ratio of the protein-bound uremic toxin kynurenic acid

    The plasma reduction ratio of kynurenic acid will be calculated using the plasma concentrations before and after WEAKID treatment.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  32. The plasma reduction ratio of the protein-bound uremic toxin hippuric acid

    The plasma reduction ratio of hippuric acid will be calculated using the plasma concentrations before and after WEAKID treatment.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  33. The release of base

    The release of base (in mmol) will be determined by calculating the sum of the release of bicarbonate (in mmol) and that of lactate (in mmol) for each WEAKID treatment

    Time frame: This will be assessed for every WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  34. Evolution of plasma levels of urea

    Urea plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  35. Evolution of plasma levels of creatinine

    Creatinine plasma levels (in micromol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  36. Evolution of plasma levels of uric acid

    Uric acid plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  37. Evolution of plasma levels of beta-2 microglobulin

    Beta-2 microglobulin plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  38. Evolution of plasma levels of phosphate

    Phosphate plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  39. Evolution of plasma levels of potassium

    Potassium plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  40. Evolution of plasma levels of bicarbonate

    Bicarbonate plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  41. Evolution of plasma levels of lactate

    Lactate plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  42. Evolution of plasma levels of sodium

    Sodium plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  43. Evolution of plasma levels of chloride

    Chloride plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  44. Evolution of plasma levels of calcium

    Calcium plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  45. Evolution of plasma levels of magnesium

    Magnesium plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  46. Evolution of plasma levels of glucose

    Glucose plasma levels (in mmol/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  47. Evolution of plasma levels of lactate dehydrogenase

    Lactate dehydrogenase plasma levels (in U/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  48. Evolution of plasma levels of vitamin B12

    Vitamin B12 plasma levels (in mg/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  49. Evolution of plasma levels of albumin

    Albumin plasma levels (in g/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  50. Evolution of plasma leucocyte count

    Leucocyte count in plasma (in x10\^9/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  51. Evolution of plasma thrombocyte count

    Thrombocyte count in plasma (in x10\^9/L) will be determined before and after every WEAKID session.

    Time frame: These will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)

  52. Evolution of plasma levels of C-reactive protein (CRP)

    CRP plasma levels (in mg/L) will be determined before and after every series of three WEAKID sessions.

    Time frame: This will be assessed before and after every series of three WEAKID treatment throughout the study treatment period (two times per week, two weeks in total per participant)

  53. Evolution of plasma levels of bilirubin

    Bilirubin plasma levels (in umol/L) will be determined before and after every series of three WEAKID sessions.

    Time frame: This will be assessed before and after every series of three WEAKID treatment throughout the study treatment period (two times per week, two weeks in total per participant)

  54. Evolution of plasma levels of aspartate transaminase (ASAT)

    ASAT plasma levels (in U/L) will be determined before and after every series of three WEAKID sessions.

    Time frame: This will be assessed before and after every series of three WEAKID treatment throughout the study treatment period (two times per week, two weeks in total per participant)

  55. Evolution of plasma levels of alanine aminotransferase (ALAT)

    ALAT plasma levels (in U/L) will be determined before and after every series of three WEAKID sessions.

    Time frame: This will be assessed before and after every series of three WEAKID treatment throughout the study treatment period (two times per week, two weeks in total per participant)

  56. Evolution of sodium levels in dialysate effluent

    Sodium levels (in mmol/L) will be determined in dialysate effluent at various timepoints during every WEAKID treatment.

    Time frame: This will be assessed during WEAKID treatment at t=15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  57. Evolution of chloride levels in dialysate effluent

    Chloride levels (in mmol/L) will be determined in dialysate effluent at various timepoints during every WEAKID treatment.

    Time frame: This will be assessed during WEAKID treatment at t=15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  58. Evolution of calcium levels in dialysate effluent

    Calcium levels (in mmol/L) will be determined in dialysate effluent at various timepoints during every WEAKID treatment.

    Time frame: This will be assessed during WEAKID treatment at t=15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  59. Evolution of magnesium levels in dialysate effluent

    Magnesium levels (in mmol/L) will be determined in dialysate effluent at various timepoints during every WEAKID treatment.

    Time frame: This will be assessed during WEAKID treatment at t=15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  60. Evolution of bicarbonate levels in dialysate effluent

    Bicarbonate levels (in mmol/L) will be determined in dialysate effluent at various timepoints during every WEAKID treatment.

    Time frame: This will be assessed during WEAKID treatment at t=15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  61. Evolution of lactate levels in dialysate effluent

    Lactate levels (in mmol/L) will be determined in dialysate effluent at various timepoints during every WEAKID treatment.

    Time frame: This will be assessed during WEAKID treatment at t=15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  62. Evolution of pH of dialysate effluent

    pH of dialysate effluent will be determined at various timepoints during every WEAKID treatment.

    Time frame: This will be assessed during WEAKID treatment at t=15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  63. Total number of device deficiencies and adverse device effects

    All device deficiencies (DDs) and adverse device effects (ADEs) will be reported and quantified.

    Time frame: This will be assessed through study completion (four weeks in total per participant)

  64. Evolution of delta intraperitoneal pressure during WEAKID treatment

    Delta intraperitoneal pressure will be calculated using the following formula: intraperitoneal pressure during WEAKID treatment (in mbar) - intraperitoneal pressure at t=0 (in mbar). Intraperitoneal pressure is determined using the pressure sensors of the WEAKID device.

    Time frame: This will be assessed during WEAKID treatment at t=15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours (for 8-hour treatment), and 8 hours (for 8-hour treatment) throughout the study treatment period (2 weeks in total per participant)

  65. Patient tolerance (abdominal discomfort)

    Abdominal discomfort (scored using a numeric rating scale between 0-10) will be determined multiple times throughout the study period.

    Time frame: This will be assessed at baseline, during every WEAKID treatment (at t = 0 minutes, 15 minutes, 1 hour, 2 hours, 4 hours, and 8 hours (for 8-hour treatment), and at the end of the study period (4 weeks in total per participant).

  66. Evolution of uremic symptoms

    Uremic symptoms will be scored using the Dialysis Symptom Index questionnaire; this is a questionnaire consisting of thirty yes/no questions regarding whether participants have experienced a certain symptom during the last week. If the answer is yes, the participant will score how much they have felt burdened by this specific symptom during the last week on a Likert scale from 0-4; the higher the score, the more burdened the participant felt.

    Time frame: This will be assessed at baseline and on the day of the last WEAKID treatment of each treatment week (three times during three weeks in total per participant).

Other outcomes

  1. Baseline characteristics

    At baseline, demographical, clinical, and laboratory data will be collected. These include age, gender, body mass index, blood pressure, heart rate, oxygen saturation, body temperature, medication usage, medical history (including cause of kidney failure and comorbidity scored using the Charlsons' and Davies' indices, residual kidney function, renal clearance, renal weekly Kt/V, estimated glomerular filtration rate, and dialysis-related data (duration of dialysis, PD treatment modality and scheme, peritoneal catheter type, history of peritoneal catheter dysfunction or infection, dialysis adequacy, and peritoneal weekly Kt/V.

    Time frame: These will be assessed at baseline

  2. Peritoneal equilibrium tests

    The standard peritoneal membrane analysis will be performed to determine the function of the peritoneal membrane.

    Time frame: This will be assessed once at baseline and once the week after the last WEAKID treatment week (four weeks in total per participant).

08

Study locations

1 of 3 sites recruiting
09

References and documents

Publications

  • van Gelder MK, Ligabue G, Giovanella S, Bianchini E, Simonis F, Hazenbrink DHM, Joles JA, Bajo Rubio MA, Selgas R, Cappelli G, Gerritsen KGF. In vitro efficacy and safety of a system for sorbent-assisted peritoneal dialysis. Am J Physiol Renal Physiol. 2020 Aug 1;319(2):F162-F170. doi: 10.1152/ajprenal.00079.2020. Epub 2020 Jun 1. PubMed 32475132 ↗
  • van Gelder MK, de Vries JC, Simonis F, Monninkhof AS, Hazenbrink DHM, Ligabue G, Giovanella S, Joles JA, Verhaar MC, Bajo Rubio MA, Selgas R, Cappelli G, Gerritsen KGF. Evaluation of a system for sorbent-assisted peritoneal dialysis in a uremic pig model. Physiol Rep. 2020 Dec;8(23):e14593. doi: 10.14814/phy2.14593. PubMed 33278069 ↗

Individual participant data

Plan to share: Yes — Raw data will only be available to other researchers upon request and after approval of the Principal Investigator since the data is privacy-sensitive (pseudonymized) and commercially sensitive.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: The following data will be shared (under restrictions if seen fit by the Principal Investigator) upon request: The raw data The study protocol describing the methods and materials The script to process the data The scripts leading to tables and figures in the publication A codebook with explanations on the variable names A 'read_me.txt' file with an overview of files included and their content and use. The time period will be determined on a case-by-case basis. A data sharing agreement outlining the terms of use for the receiving party will be drawn up before data is transferred.

Access criteria: Data will be shared upon request after approval from the PI. The access criteria will be determined on a case-by-case basis.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 23 months is close to that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2024
First posted
Mar 18, 2024
StartActual
Jan 22, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jul 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06314503
Lead sponsor
UMC Utrecht
Collaborators
Horizon 2020 - European Commission, Dutch Kidney Foundation, Health Holland, Nanodialysis Ltd, University of Modena and Reggio Emilia, Servicio Madrileno De Salud (SERMAS), PPI Healthcare Consulting Ltd
Responsible party
Karin G.F. Gerritsen (MD, PhD, Associate professor, UMC Utrecht) — Principal investigator
First posted
Mar 18, 2024
Start date
Jan 22, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jul 18, 2025

Study contacts

Karin GF Gerritsen, MD. PhD
Contact
k.g.f.gerritsen@umcutrecht.nl
+31887557375
Dian P Bolhuis, MSc
Contact
d.p.bolhuis-3@umcutrecht.nl
+31887557375
Karin GF Gerritsen, MD, PhD
principal investigator · UMC Utrecht

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion